Hyperhomocysteinemia is an independent risk factor for cardiovascular disease in human diabetes. Among the multiple factors that may account for the atherogenicity of homocysteine (Hcys) in patients with diabetes, macrophage (Mo) lipoprotein lipase (LPL) has unique features in that it is increased in human diabetes and acts as a proatherogenic factor in the arterial wall. In the present study, we determined the direct regulatory effect of Hcys on Mo LPL gene expression and secretion. 
C ardiovascular diseases are the leading causes of morbidity and mortality in patients with diabetes. The high risk of cardiovascular disease in these individuals cannot be totally explained by classic risk factors. Hyperhomocysteinemia is an independent risk factor for cardiovascular disease in the general population (1) (2) (3) (4) (5) . In the diabetic population, the association between hyperhomocysteinemia and cardiovascular disease seems even stronger (6 -10) . Furthermore, this risk factor may predict mortality in patients with type 2 diabetes (9, 10) .
Several mechanisms have been proposed to explain the atherogenic properties of homocysteine (Hcys). In particular, it has been shown that Hcys promotes smooth muscle cell proliferation (11) ; activates the protein kinase C (PKC)/c-fos signaling pathway (12) ; and induces platelet aggregation (13) , lipoprotein oxidation, and activation of the coagulation pathway (13) .
Lipoprotein lipase (LPL), a key enzyme in lipid metabolism, is secreted by macrophages (Mo) in atherosclerotic lesions (14) . Mo LPL produced in the vascular wall acts as a proatherogenic protein. Indeed, this enzyme mediates the uptake of lipoproteins by Mo (15) (16) (17) , promotes lipoprotein retention to the extracellular matrix (18, 19) , induces the expression of the proatherogenic cytokine tumor necrosis factor-␣ (20, 21) , increases monocyte adhesion to endothelial cells (22) (23) (24) , and increases proliferation of vascular smooth muscle cells (25) . Recent evidence shows that Mo LPL promotes foam cell formation and atherosclerosis in vivo (26 -29) . The regulation of Mo LPL in the arterial wall is poorly understood but may involve metabolic factors. This hypothesis is supported by our previous findings that Mo LPL is increased in patients with type 2 diabetes (30) and that metabolic factors dysregulated in diabetes, such as glucose (31) and fatty acids (32) , enhance Mo LPL expression. On the basis of these findings and of the high levels of serum Hcys in patients with diabetes, we sought to evaluate the direct regulatory effect of Hcys on Mo LPL expression and to determine the molecular mechanism(s) involved in this effect.
cold phosphate-buffered salt solution, and lysed in 1 ml of ice-cold buffer A (15 mmol/l KCL, 2 mmol/l MgCl 2 , 10 mmol/l HEPES, 0.1% phenylmethylsulfonyl fluoride, and 0.5% Nonidet-P-40). After a 10-min incubation on ice, lysed cells were centrifuged, and the nuclei were washed with buffer A without Nonidet P-40. The nuclei were then lysed in a buffer containing 2 mol/l KCL, 25 mmol/l HEPES, 0.1 mmol/l EDTA, and 1 mmol/l dithiothreitol (DTT). After a 15-min incubation period, a dialysis buffer (25 mmol/l HEPES, 1 mmol/l DTT, 0.1% phenylmethylsulfonyl fluoride, 2 g/ml aprotinin, 0.1 mmol/l EDTA, and 11% glycerol) was added to the nuclei preparation. Nuclei were collected by centrifugation for 20 min at 13,000 rpm. Aliquots (50 l) of the supernatants were frozen at Ϫ70°C, and protein concentration was determined. DNA retardation (mobility shift) electrophoresis assays were performed as previously described by Fried and Crothers (34) . Briefly, 5 g of nuclear extracts was incubated for 15 min in the presence of 5ϫ binding buffer (125 mmol/l HEPES [pH 7.5], 50% glycerol, 250 mmol/l NaCl, 0.25% Nonidet P-40, and 5 mmol/l DTT). End-labeled double-stranded consensus sequences of the LPL promoter AP-1-enhancing element (20,000 cpm per sample) were then added to the samples for 30 min. Samples were analyzed on a 4% nondenaturing polyacrylamide gel containing 0.01% Nonidet P-40. The specificity of the nuclear protein binding was assessed by incubating the nuclear proteins isolated from murine Mo with labeled DNA probe in the presence of a 1,000-fold molar excess of unlabeled DNA probe. DNA probes. The cDNA probe for detection of murine LPL was prepared by the polymerase chain reaction technique. cDNA was obtained from total RNA using a reverse transcription reaction. Two synthetic primers spanning bases 255-287 and 1,117-1,149 of the LPL cDNA were used to enzymatically amplify a 894-bp region of the LPL probe. The cDNA probes for murine c-fos and GAPDH were purchased from American Type Culture Collection. A 20-mer double-stranded oligonucleotide (5Ј-GGGCACCT GACTAAGGCCAG-3Ј; 5Ј-TGTGCTGGCCTTAGTCAGGT-3Ј) containing the consensus sequence for the AP-1-responsive element of the murine LPL gene promoter (35, 36) was synthesized with the aid of an automated DNA synthesizer. After annealing, the double-stranded oligonucleotide was labeled with [␥-32 P]ATP by using the Boehringer Mannheim 5Ј end-labeling kit (Indianapolis, IN). Determination of human LPL immunoreactive mass and activity. One hour before the end of the incubation period, 50 units/ml heparin was added to the medium. The amount of LPL immunoreactive mass was measured by enzyme-linked immunosorbent assay using the Markit-F LPL kit (Dainippon, Pharmaceutical, Osaka, Japan) (37) . Extracellular LPL activity was determined using the Confluolip kit (Progen, Heidelberg, Germany) (38) . LPL mass and activity values were normalized to the levels of total cell proteins. Measurement of PKC activity. Adherent murine J774 Mo were recovered and homogenized (Dounce: 15 strokes) in 500 l of ice-cold buffer A (20 mmol/l Tris [pH 7.5], 0.5 mmol/l EDTA, 0.5 mmol/l EGTA, 25 g/ml aprotinin, and 25 g/ml leupeptin). The membrane and cytosolic fractions were separated by ultracentrifugation (100,000g for 30 min at 4°C). After recovery of high-speed supernatants containing cytosolic PKC, the corresponding membrane pellets were homogenized in 500 l of buffer A containing 0.5% Triton X-100. The enzyme from both fractions was partially purified through DE52 chromatography columns. After removal of unbound proteins by washing of the columns with buffer B (20 mmol/l Tris [pH 7.5], 0.5 mmol/l EDTA, 0.5 mmol/l EGTA, and 10 mmol/l ␤-mercaptoethanol), fractions containing PKC were eluted with buffer C (Tris [pH 7.5], 0.5 mmol/l EDTA, 0.5 mmol/l EGTA, 10 mmol/l ␤-mercaptoethanol, and 0.2 mol/l NaCl). Eluates were analyzed for PKC activity, following the optimum conditions of the assay, by measuring the incorporation of 32 P into the synthetic peptide Ac-myelin basic protein (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . The specificity of the assay was determined by subtracting the radioactivity obtained in the presence of the pseudosubstrate inhibitor PKC(19-36) from total radioactivity. PKC activity was normalized to the levels of total cell proteins. Data were expressed as percentages, considering the control as 100% activity. Determination of total protein concentrations. Total protein content was measured according to the Bradford method (39) using a colorimetric assay (Bio-Rad, Mississauga, Ontario, Canada). Statistical analysis. All values were expressed as the mean Ϯ SE. Data were analyzed by Student's t test for comparison of two groups or by one-way ANOVA followed by the Student-Newman-Keuls test or the Dunn's method for multiple comparisons. A value of P Ͻ 0.05 was considered significant.
RESULTS
Effect of Hcys on Mo LPL mRNA expression. Incubation of J774 cells for 1-24 h with Hcys increased Mo LPL gene expression in a time-dependent manner. Induction of Mo LPL mRNA levels in response to Hcys (1-5 mmol/l) was biphasic, peaking at 1 and 6 h (Fig. 1A) . Maximal effect was observed after a 6-h incubation period in the presence of 5 mmol/l Hcys. Under these experimental conditions, no modulation of the mRNA expression of GAPDH, used as internal control, was observed. LPL mRNA levels normalized to the levels of GAPDH mRNA are illustrated in in Mo LPL mRNA levels was detected after a 30-min incubation period with Hcys. Maximal effect was observed at the 45-and 60-min incubation periods. LPL mRNA levels normalized to the levels of GAPDH are presented in (Fig. 2B) . Time-dependent effect of Hcys on Mo LPL mass and activity. Mo exposed for 24 -72 h to Hcys (1-5 mmol/l) showed a sustained twofold increase in LPL mass secretion (Fig. 3A) . Determination of Mo LPL activity in the supernatants of J774 cells exposed to 5 mmol/l Hcys showed a moderate increase in this parameter (Fig. 3B) . In contrast, the levels of extracellular LPL activity in cells treated with 1 mmol/l Hcys remained unchanged (Fig. 3B) . Role of PKC on Hcys-stimulated LPL gene expression. To determine whether PKC may represent the signaling pathway involved in the upregulation of Mo LPL gene expression by Hcys, we pretreated J774 cells for 30 min in the presence or absence of the specific PKC inhibitor Calphostin C (0.5 g/ml), and then we treated cells for 1 h with 1 mmol/l Hcys. As shown in To establish further the involvement of PKC in Hcysstimulated Mo LPL mRNA expression, we measured PKC activity in cytosolic and particulate fractions of Hcystreated J774 cells (Fig. 4B) . A maximal increase in PKC activity in the membrane fraction of Mo was observed after a 10-min exposure of the cells to 1 mmol/l Hcys. Effect of Hcys on Mo c-fos mRNA levels. To assess the effect of Hcys on Mo c-fos gene expression, we incubated J774 cells for 15 to 60 min with 1 mmol/l Hcys (Fig. 5A) . Exposure of Mo for 15 min to Hcys led to a significant induction of basal c-fos gene expression. Maximal effect was observed after a 30-to 45-min incubation period. As illustrated in Fig. 5B , induction of Mo c-fos gene expression was dose-dependent, with a maximal effect occurring at a Hcys concentration of 1 mmol/l. Effect of Hcys on the binding of nuclear proteins to the regulatory AP-1 sequence of the murine LPL gene promoter. We next determined whether incubation of J774 cells in the presence of Hcys might induce changes at the level of LPL gene promoter binding proteins. We found that a 15-to 30-min exposure of J774 cells to Hcys led to a major increase in the binding of nuclear proteins to the AP-1 consensus sequence of the LPL promoter. Maximal effect was observed after a 15-min incubation period (Fig.  6 ). This binding complex was specifically competed in the presence of a 1,000-fold molar excess of the unlabeled AP-1 oligonucleotide. 
DISCUSSION
Hyperhomocysteinemia is an independent risk factor for cardiovascular disease (1) (2) (3) (4) (5) . Although Hcys has been implicated in many biological events associated with atherogenesis, the mechanism(s) by which this amino acid exerts its proatherogenic effects is still not well known.
Our results demonstrate, for the first time, that Hcys stimulates Mo LPL secretion in vitro. This observation is relevant in light of recent studies showing that Mo LPL production in the arterial wall promotes foam cell formation and atherosclerosis in vivo (26 -29) . Our finding that Hcys induces to a similar extent LPL mRNA levels and LPL mass suggests that the stimulatory effect of Hcys on Mo LPL secretion may, at least partly, involve transcriptional events. It is widely known that the regulation of LPL gene expression is controlled by several cis-and trans-acting factors surrounding the LPL transcriptional start site (40, 41) . Induction of LPL gene expression by Hcys may theoretically involve different signaling pathways. On the basis of the presence of an AP-1 site in the regulatory sequence of the LPL gene and of the previously documented effect of Hcys on PKC and c-fos activation (12), one may suggest that increased AP-1 activity resulting from PKC-induced c-fos expression could mediate the stimulatory effect of Hcys on Mo LPL gene expression. Our findings that Hcys led to PKC activation in Mo and that specific PKC inhibitors totally abolished the induction of Mo LPL gene expression in response to Hcys clearly demonstrated that PKC activation is required for the stimulatory effect of Hcys on Mo LPL gene expression. Furthermore, our observations that Hcys induces parallel changes in Mo LPL and c-fos mRNA levels and that Hcys induces the binding of nuclear proteins to the AP-1 sequence suggest a role for c-fos in the transcriptional regulation of Mo LPL gene expression by Hcys. From these observations, one may postulate that one signaling event mediating the increase of the transcriptional rate of the LPL gene in response to Hcys involves the activation of PKC and the interaction of its well-known target c-fos with the AP-1 sequence. Several lines of evidence indicate that PKC activates the mitogen-activated protein (MAP) kinase signal transduction pathway and that induction of MAP kinase activity results subsequently in c-fos expression. Members of the MAP kinase family include the extracellular signal-regulated kinases (ERKs) 1 and 2 and the stress-induced kinases Jun NH 2 -terminal kinase and p38. It has been demonstrated that Hcys activates the Jun NH 2 -terminal kinase signaling pathway in human endothelial cells (42) and stimulates ERK1 and -2 phosphorylation in smooth muscle cells and NIH/3T3 cells (43) (44) (45) . On the basis of these findings and on the previously documented role of the MAP kinase pathway in the regulation of adipocyte LPL expression (46) , it is tempting to speculate that PKC-dependent MAP kinase activation could mediate the upregulation of Mo LPL gene expression by Hcys. This question is especially relevant considering the close correlation between the reported biphasic activation of ERK, which rises 10 min and 4 h after stimulation (47) , and the presently documented Hcys-induced early and delayed stimulation of Mo LPL gene expression that we observed at 1 and 6 h after Hcys exposure, respectively.
Besides c-fos, other transcription factors, such as peroxisome-proliferator activated receptors (PPARs), could mediate the upregulation of Mo LPL gene expression in response to Hcys. Indeed, evidence has been provided that PPARs regulate Mo LPL gene expression (32, 48) by binding to a peroxisome-proliferator response element present in the LPL promoter (49) . Because Hcys (50), PKC (51, 52) , and MAP kinases (53-57) regulate the expression and/or activation of PPARs, these transcription factors may play a key role in the upregulation of Mo LPL gene expression in response to Hcys. Our preliminary observations showing that Hcys induces the binding of nuclear proteins to the peroxisome-proliferator response element of the LPL gene support this possibility.
Our results finally demonstrated that Hcys increases Mo LPL secretion. Whereas the increment of LPL mass paralleled the induction in LPL mRNA, increase of LPL activity was not observed in cells exposed to 1 mmol/l Hcys and was well below the reported elevation in the enzyme mRNA levels in Mo treated with 5 mmol/l Hcys. Because the antibody used to measure LPL mass recognized both active and inactive LPL, these findings suggest that Hcys induces the release of mostly inactive LPL. The complex posttranslational processing of LPL allows for the expectation of different sites for this modulation of LPL activity by Hcys. Additional research will be necessary to determine exactly which steps of the process of LPL synthesis are target sites for the modulation of LPL activity by Hcys.
Recent data suggest that Hcys may be a risk factor for cardiovascular disease in the diabetic population. Plasma Hcys concentrations are elevated in patients with diabetes (58, 59) , and a relationship between hyperhomocysteinemia and increased risk of cardiovascular morbidity and mortality has been established in patients with type 2 diabetes (6 -10). We previously demonstrated that Mo LPL, a proatherogenic protein, is increased in patients with type 2 diabetes (30) and that peripheral factors are, at least partly, responsible for this alteration (30 -32) . Our finding that Hcys increases Mo LPL secretion in vitro suggests that Hcys may contribute to the induction of Mo LPL in human diabetes.
One limitation of the present study is the supraphysiological Hcys concentrations needed to enhance Mo LPL expression in vitro. Indeed, we found that the DL-Hcys concentrations required to stimulate Mo LPL in the present study were Ͼ10 times those found in the plasma of patients with diabetes. Because the inactive D-isomer constitutes ϳ50% of the DL-Hcys, use of the L-isomer of Hcys exclusively could have lowered the Hcys concentration needed to elicit a biological response. It is also possible that concentrations of Hcys in the limited environment of the atherosclerotic plaque may be sufficient to favor the induction of Mo LPL in vivo. Because LPL exerts its proatherogenic effects through both its structural and catalytic properties (60 -65) , generation of increased amounts of LPL, even in its inactive form, may contribute to the accelerated atherosclerosis associated with diabetes.
In conclusion, this study demonstrates for the first time that Hcys stimulates Mo LPL gene expression and secretion in vitro. Our data show that induction of Mo LPL mRNA expression by Hcys involves PKC activation and suggest a role of c-fos in the transcriptional regulation of Mo LPL expression. These results provide a new mechanism by which Hcys may promote atherosclerosis in human diabetes.
